While the US FDA has yet to object to a prescription drug promotion on a mobile device, the agency may pay closer attention to such communications in the wake of an agency study that found they do not equally convey a product's benefits and risks.
The agency's Office of Prescription Drug Promotion (OPDP) analyzed 51 promotional communications from May 2012 to May 2014 on smartphones,...